Literature DB >> 8344199

Synthetic antiestrogens modulate induction of pS2 and cathepsin-D messenger ribonucleic acid by growth factors and adenosine 3',5'-monophosphate in MCF7 cells.

D Chalbos1, A Philips, F Galtier, H Rochefort.   

Abstract

In MCF7 human breast cancer cells, the antiestrogens 4-hydroxy-tamoxifen and ICI 164,384 inhibit the mitogenic activity of epidermal growth factor (EGF) and insulin-like growth factor-I (IGF-I). These growth factors also stimulate the expression of cathepsin-D and pS2 genes. Therefore, we studied the effects of antiestrogens on growth factor induction of pS2 and cathepsin-D mRNA. The two antiestrogens strongly inhibited the transcriptional induction of pS2 by growth factors. On the contrary, estradiol and IGF-I or EGF had an additive effect on pS2 mRNA accumulation. Growth factor induction of cathepsin-D was also inhibited by ICI 164,384. By contrast, 4-hydroxytamoxifen had an agonist effect on cathepsin-D and an additive effect on IGF-I-induced mRNA. When 12-O-tetradecanoylphorbol-13-acetate or 8-bromo-cAMP (8-Br-cAMP) was used instead of growth factors, similar effects of 4-hydroxytamoxifen and ICI 164,384 were obtained on pS2 (12-O-tetradecanoylphorbol-13-acetate and 8-Br-cAMP) and cathepsin-D (8-Br-cAMP) induction. A mechanism based on the classical competitive inhibition by antiestrogens of estrogen binding and action on the estrogen receptor was very unlikely, as 1) no antigrowth factor activity was obtained with R5020, which was a potent inhibitor of estrogen induction of pS2 and cathepsin-D mRNA; 2) in the Ishikawa endometrial cancer cell line, the cathepsin-D gene is unresponsive to estrogen, but was inhibited by antiestrogen after its induction by EGF or 8-Br-cAMP; and 3) the residual estrogen concentration in cells was too low to induce the expression of estrogen-specific genes. However, antiestrogens did not inhibit the expression of all genes induced by growth factors, as they were without effect on IGF-I induction of glyceraldehyde-3-phosphate dehydrogenase mRNA. These results demonstrate that antiestrogens can modulate the transcription of some growth factor-induced genes and strongly suggest that this effect is not due to interference with residual estrogens.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8344199     DOI: 10.1210/endo.133.2.8344199

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  9 in total

1.  Antiestrogen inhibition of EGF-mediated invasiveness of human breast cancer cells.

Authors:  G M Tong; T T Rajah; X Zang; J T Pento
Journal:  In Vitro Cell Dev Biol Anim       Date:  2001-10       Impact factor: 2.416

2.  Binding of TATA binding protein to a naturally positioned nucleosome is facilitated by histone acetylation.

Authors:  G F Sewack; T W Ellis; U Hansen
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

3.  Overexpression of insulin-like growth factor II (IGFII) in ZR-75-1 human breast cancer cells: higher threshold levels of receptor (IGFIR) are required for a proliferative response than for effects on specific gene expression.

Authors:  K Abdul-Wahab; D Corcoran; A Perachiotti; P D Darbre
Journal:  Cell Prolif       Date:  1999-10       Impact factor: 6.831

4.  Steroid hormone receptors and their clinical significance in cancer.

Authors:  R I Nicholson; R A McClelland; J M Gee
Journal:  J Clin Pathol       Date:  1995-10       Impact factor: 3.411

5.  Gender difference in the activity but not expression of estrogen receptors alpha and beta in human lung adenocarcinoma cells.

Authors:  Susan M Dougherty; Williard Mazhawidza; Aimee R Bohn; Krista A Robinson; Kathleen A Mattingly; Kristy A Blankenship; Mary O Huff; William G McGregor; Carolyn M Klinge
Journal:  Endocr Relat Cancer       Date:  2006-03       Impact factor: 5.678

6.  Immunoradiometric and immunohistochemical analysis of Cathepsin D in ovarian cancer: lack of association with clinical outcome.

Authors:  G Ferrandina; G Scambia; A Fagotti; G D'Agostino; P Benedetti Panici; A Carbone; S Mancuso
Journal:  Br J Cancer       Date:  1998-12       Impact factor: 7.640

7.  Trefoil factor 1 in early breast carcinoma: a potential indicator of clinical outcome during the first 3 years of follow-up.

Authors:  Milan Markićević; Radan Džodić; Marko Buta; Ksenija Kanjer; Vesna Mandušić; Zora Nešković-Konstantinović; Dragica Nikolić-Vukosavljević
Journal:  Int J Med Sci       Date:  2014-05-01       Impact factor: 3.738

8.  Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels.

Authors:  John T Sigalos; Alexander W Pastuszak; Andrew Allison; Samuel J Ohlander; Amin Herati; Mark C Lindgren; Larry I Lipshultz
Journal:  Am J Mens Health       Date:  2017-08-22

9.  Variation of hormonal receptor, pS2, c-erbB-2 and GSTpi contents in breast carcinomas under tamoxifen: a study of 74 cases.

Authors:  I Soubeyran; N Quénel; L Mauriac; M Durand; F Bonichon
Journal:  Br J Cancer       Date:  1996-03       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.